de Geus, Matthijs B.
Leslie, Shannon N.
Lam, TuKiet
Wang, Weiwei
Roux-Dalvai, Florence
Droit, Arnaud
Kivisakk, Pia
Nairn, Angus C.
Arnold, Steven E.
Carlyle, Becky C.
Funding for this research was provided by:
National Institutes of Health (AG062306, AG062421)
Article History
Received: 6 September 2023
Accepted: 7 December 2023
First Online: 16 December 2023
Competing interests
: S. Arnold has received honoraria and/or travel expenses for lectures from Abbvie, Eisai, and Biogen and has served on scientific advisory boards of Corte, has received consulting fees from Athira, Cassava, Cognito Therapeutics, EIP Pharma and Orthogonal Neuroscience, and has received research grant support from NIH, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Abbvie, Amylyx, EIP Pharma, Merck, Janssen/Johnson & Johnson, Novartis, and vTv. S.N. Leslie is a current employee of Janssen Pharmaceuticals. B. Carlyle has received grant funding from Ono Pharmaceutical. Other authors report no conflicts of interest.